NCT04576000终止不适用
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Identify predictive blood biomarkers that are associated with a change from baseline in UC-100 score
研究概览
简要总结
This study aims to provide new mechanistic insights into the molecular determinants of response or nonresponse to Janus Kinase inhibitor therapy and the biological heterogeneity that exists in Ulcerative Colitis. This study will include patients who are initiating Janus Kinase inhibitor therapy according to standard of care. This study consists of:
- Part 1: 8 or 10 week induction therapy followed by an 8-week maintenance therapy
- Part 2: Patients who continue Janus Kinas inhibitor therapy after part 1 will be followed further for a total of 2 years, or until discontinuation of Janus Kinase inhibitor therapy (whichever is first)
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.18 years of age or older.
- •2.Male or nonpregnant, nonlactating females.
- •3.Diagnosis of Ulcerative Colitis for at least 3 months prior to screening.
- •4.Moderately to severely active Ulcerative Colitis (total Mayo Clinic Score ≥ 6), with objective evidence of inflammation defined by a Mayo endoscopic subscore (MES) ≥ 2 and disease extending > 15 cm from the anal verge.
- •5.Physician plans to administer Janus Kinase inhibitor for at least 8 weeks of induction therapy as part of Standard of Care (SOC).
- •6.Documentation of a negative test result for latent tuberculosis within the last 12 months, or according to routine clinical practice.
- •7.Able to participate fully in all aspects of this clinical trial, including collection of tissue biopsies.
- •8.Written informed consent must be obtained and documented.
排除标准
- •Diagnosis of Crohn's disease or indeterminate colitis.
- •An active, serious infection, including localized infections.
- •Concomitant administration of biological therapies for Ulcerative Colitis or potent immunosuppressants, such as azathioprine and cyclosporine. Subjects with previous exposure to these treatments should undergo an appropriate washout period according to local practice prior to starting Janus Kinase inhibitor, in keeping with routine clinical practice.
- •Hematology laboratory (e.g., absolute lymphocyte count, absolute neutrophil count, and hemoglobin that contraindicate the product label.
- •Interval between live vaccinations and initiation of tofacitinib therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.
- •Serious underlying disease other than Ulcerative Colitis that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study.
研究组 & 干预措施
Open-Label Group
Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.
干预措施: Janus Kinase Inhibitor (Drug)
结局指标
主要结局
Identify predictive blood biomarkers that are associated with a change from baseline in UC-100 score
时间窗: 8 or 10 weeks; 24 weeks
Identify predictive fecal biomarkers that are associated with a change from baseline in UC-100 score
时间窗: 8 or 10 weeks; 24 weeks
The UC-100 is a composite disease activity index consisting of clinical, endoscopic, and histological findings. The UC-100 is calculated by summing the weighted Mayo Clinic Score (MCS) stool frequency and endoscopy subscores, and the Robarts Histopathology Index (RHI) score as follows: UC-100 Score = 1 + (16 X stool frequency) + (6 X endoscopic subscore) + (RHI score). The total UC-100 score ranges from 1 to 100, with higher scores representing more severe disease activity.
Identify predictive tissue biomarkers that are associated with a change from baseline in UC-100 score
时间窗: 8 or 10 weeks; 24 weeks
次要结局
- Identify pharmacodynamic fecal biomarkers that are associated with a change from baseline in UC-100 score(8 or 10 weeks, 24 weeks)
- Identify pharmacodynamic blood biomarkers that are associated with a change from baseline in UC-100 score(8 or 10 weeks, 24 weeks)
- Identify a tissue biomarker signature as a surrogate measure for change from baseline in UC-100 score(8 or 10 weeks, 24 weeks)
- Determine the time-concentration profile of Janus Kinase inhibitor at steady state in tissue samples.(24 weeks)
- Evaluate correlation of exposure of Janus Kinase inhibitor between serum samples following SOC induction therapy and at Week 24.(8 or 10 weeks, 24 weeks)
- Determine the time-concentration profile of Janus Kinase inhibitor at steady state in stool samples.(24 weeks)
- Explore the exposure-response relationship of Janus Kinase inhibitors with exposure measured in serum samples and response defined as tissue PD biomarkers following SOC induction therapy and at Week 24.(8 or 10 weeks, 24 weeks)
- Identify potential demographic and disease factors affecting the most relevant JAKi exposure-response relationships and determine target threshold of systemic exposure associated with relevant clinical, endoscopic, histologic, and/or biologic outcomes.(8 or 10 weeks, 24 weeks)
- Identify pharmacodynamic tissue biomarkers that are associated with a change from baseline in UC-100 score(8 or 10 weeks, 24 weeks)
- Determine the time-concentration profile of Janus Kinase inhibitor at steady state in serum samples.(24 weeks)
- Identify a blood biomarker signature as a surrogate measure for change from baseline in UC-100 score(8 or 10 weeks, 24 weeks)
- Identify whether colonic tissue pSTAT at week 8 and/or 24 correlates with change from baseline in UC-100 score(8 or 10 weeks, 24 weeks)
- Explore the exposure-response relationship of Janus Kinase inhibitors with exposure measured in stool samples and response defined as tissue PD biomarkers following SOC induction therapy and at Week 24.(8 or 10 weeks, 24 weeks)
- Develop an exposure-response model of Janus Kinase inhibitors to characterize the relationships between local and systemic drug exposure and clinical, endoscopic, histologic, or biologic response to therapy.(24 weeks)
- Identify a fecal biomarker signature as a surrogate measure for change from baseline in UC-100 score(8 or 10 weeks, 24 weeks)
- Evaluate correlation of exposure of Janus Kinase inhibitor between stool samples following SOC induction therapy and at Week 24.(8 or 10 weeks, 24 weeks)
- Evaluate correlation of exposure of Janus Kinase inhibitors between tissue samples following SOC induction therapy and at Week 24.(8 or 10 weeks, 24 weeks)
- Explore the exposure-response relationship of Janus Kinase inhibitors with exposure measured in tissue samples and response defined as tissue PD biomarkers following SOC induction therapy and at Week 24.(8 or 10 weeks, 24 weeks)
- Evaluate long-term hospitalization rates, surgery rates, and corticosteroid use after initiation of Janus Kinase inhibitor therapy and identify baseline or early biomarker signatures associated with these long-term healthcare resource use outcomes(2 years)
- Measure adverse drug reactions, clinical, endoscopic, and histologic response and remission rates to Janus Kinase inhibitors in a "real-world" population(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDSAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT05448599Mabwell (Shanghai) Bioscience Co., Ltd.120
已完成
1 期
Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping CocktailDrug InteractionNCT02391688Jules Desmeules30
撤回
4 期
Absorption of Rivaroxaban in Patients With Cervical Spinal Cord InjurySpinal Cord InjuriesThromboembolismNCT02970773Swiss Paraplegic Research, Nottwil
已完成
1 期
In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal ProductsHIV PreventionNCT01813162CONRAD101
已完成
不适用
Exploratory study on determinant of pharmacokinetics of monoclonal antibodies in patients with advanced gastric cancerGastric cancerJPRN-UMIN000048208Keio University23